SPECIAL FEATURE

A Review of HIV Pre-Exposure Prophylaxis

Name: Relias Media
Price range: $

October 15, 2024

Human immunodeficiency virus (HIV) pre-exposure prophylaxis is a tool for preventing HIV, especially among high-risk populations. Three medication options are available. Regular screening for HIV and sexually transmitted infections is required, and adherence is crucial for effectiveness. PrEP is underused but increasingly covered by insurance, offering an important preventive option in sexual healthcare.

Issue Date: October 15, 2024

Table of Contents

Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau and advisory board for AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Novo Nordisk, and Renalytix; is on the speakers bureau for Eli Lilly; is on the advisory board for Abbott Diabetes, Phathom, Sanofi, Kowa, Haleon, and Biolinq; and is a stockholder with Paracrine. The relevant financial relationships listed for this individual have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements